Benefit of adjuvant BMA (bone modifying agents, meaning bisphosphonates and denosumab) in eBC

e-ESO Podcasts - A podcast by ESO - European School of Oncology

Categories:

Education

Expert: Michael Gnant, Comprehensive Cancer Center Vienna, Vienna, Austria Questions: 1.What is the recommendation for use of bisphosphonates in eBC? Which agents? How long? To which patients?  2.What is the benefit of adjuvant bisphosphonates in eBC (breast cancer - related outcomes and other benefit)?  3.What is the recommendation for use of denosumab in eBC?  4.What are the data to support these recommendations for practice?